On February 19, 2019, the Patented Medicine Prices Review Board (PMPRB) announced the publication of the 2017 edition of Meds Entry Watch. According to the notice, this publication provides information on new medicines entering Canadian and international markets. The 2017 edition examines the availability, sales, uptake, pricing, and treatment costs of new medicines approved by the US Food and Drug Administration, the European Medicines Agency, and/or Health Canada in 2016 and 2017, as well as trends, going back to 2009. This edition also includes an analysis of biosimilars approved between 2006 and 2017.
Related Publications & Articles
-
CIPO will not issue patents on July 9 or July 16
The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.Read More -
PMPRB releases Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines
On June 26, 2024, the Patented Medicine Prices Review Board (PMPRB) released a Discussion Guide for its Phase 2 Consultations on its New Guidelines.Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More